Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Mieczysław Dutka, Rafał Bobiński, Tomasz Francuz, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5811-5811
Open Access | Times Cited: 67
SGLT2 Inhibitors as Potential Anticancer Agents
Debasish Basak, David Gamez, Subrata Deb
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1867-1867
Open Access | Times Cited: 36
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
Min Sun, Jilei Sun, Wei Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 9
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Jisha Pillai U, Anindita Ray, Meenu Maan, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103684-103684
Closed Access | Times Cited: 16
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Research Progress of SGLT2 Inhibitors in Cancer Treatment
Xiaoyong Miao, Jianing Zhang, Weiyan Huang, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 505-514
Open Access
An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells
Zipeng Xie, Fang Wang, Lingqiang Lin, et al.
Cancer Letters (2020) Vol. 495, pp. 200-210
Closed Access | Times Cited: 45
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Kristy T. K. Lau, Lui Ng, Jason W.H. Wong, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 1121-1136
Closed Access | Times Cited: 35
Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options
Chunye Zhang, Shuai Liu, Ming Yang
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 35
Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin
Jin Zhong, Pengbo Sun, Naihan Xu, et al.
Biochemical Pharmacology (2020) Vol. 175, pp. 113856-113856
Closed Access | Times Cited: 34
Lifestyle factors, glycemic traits, and lipoprotein traits and risk of liver cancer: a Mendelian randomization analysis
Honglu Zhang, Jiyong Liu
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma
Youshi Zheng, Naishun Liao, Yuan Wu, et al.
Molecular Medicine Reports (2019)
Open Access | Times Cited: 26
SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors
George S. Q. Tan, Jedidiah I. Morton, Stephen Wood, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 6, pp. 1304-1315
Open Access | Times Cited: 2
Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death
Linlin Yin, Yonghui Xia, Ping Xu, et al.
Oncology Reports (2020) Vol. 44, Iss. 2, pp. 477-486
Open Access | Times Cited: 18
Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans
Sawako Nakachi, Shiki Okamoto, Keita Tamaki, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 149, pp. 112864-112864
Open Access | Times Cited: 8
Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
Mu‐Chi Chung, Hui‐Tsung Hsu, Chao‐Hsiang Chang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Targeting Metabolic Pathways in Kidney Cancer
Christian R. Hoerner, Susanna Miao, James J. Hsieh, et al.
The Cancer Journal (2020) Vol. 26, Iss. 5, pp. 407-418
Closed Access | Times Cited: 8
Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study
Oscar Hou In Chou, Jing Ning, Raymond Chan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
Sidar Çöpür, Abdullah Burak Yıldız, Adrian Covic, et al.
European Journal of Clinical Investigation (2023)
Open Access | Times Cited: 2
Role of gliflozins on hepatocellular carcinoma progression: a systematic synthesis of preclinical and clinical evidence
Livia Basile, Rossella Cannarella, Paolo Magni, et al.
Expert Opinion on Drug Safety (2024), pp. 1-14
Closed Access
Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Joji Tani, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1279-1298
Open Access | Times Cited: 3
Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, et al.
GastroHep (2021) Vol. 3, Iss. 4, pp. 261-269
Closed Access | Times Cited: 2
Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
Norio Akuta, Yusuke Kawamura, Yasuji Arase, et al.
Kanzo (2019) Vol. 61, Iss. 1, pp. 24-27
Open Access | Times Cited: 1
Antidiabetic Treatments for Diabetes with Liver Cirrhosis
Yoshio Sumida
Interventions in Obesity & Diabetes (2020) Vol. 3, Iss. 4
Open Access | Times Cited: 1
Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
Dan Nakano, Takumi Kawaguchi, Tsubasa Tsutsumi, et al.
JGH Open (2022) Vol. 6, Iss. 4, pp. 270-273
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top